期刊文献+

蛋白芯片法检测肺感染患者多肿瘤标志物的变化 被引量:1

Analysis of multiple tumor markers in patient with pulmonary infection
原文传递
导出
摘要 目的:探讨肺感染患者多肿瘤标志物的变化及临床意义。方法:采用C12检测20例老年肺感染合并胸水患者、25肺感染无胸水患者、30例无肺部病变健康人12种肿瘤标志物水平。结果:肺感染无胸水组、肺感染合并胸水组血清ferritin浓度均显著高于对照组(P均<0.01),而这两组间差异无统计学意义。合并胸水组的血清CA125、CA15-3浓度均显著高于对照组和肺感染无胸水组(P<0.05,P<0.01),而对照和肺感染无胸水组间这两个指标比较无显著差异。其它指标各组间比较均无显著差异。肺感染合并胸水组,胸水中ferritin、CA125的浓度分别为281.3±103.2和389.1±71.1,均显著高于对应病例血清水平(P均<0.01)。血清与胸水间只有ferritin有相关性r=0.537,P<0.05。结论:肺感染患者血清某些肿瘤标志物异常,其血清浓度升高与胸水生成有关。 Objective:To explore the change and clinic significance of multiple tumor markers in patient with pulmonary infection.Methods: Patients with only pulmonary infection group(25),pulmonary infection combined pleural fluid group(20),and control group(30) were enrolled.Twelve tumor markers in serum and pleural fluid(AFP,CEA,NSE,CAl25,CAl53,CA242,CAl99,PSA,f-PSA,FER,β-HCG and HGH) were measured by the multi-tumor markers protein biochip detective system.Results: The serum concentration of ferritin in the two pulmonary infection group was significantly higher than that in control group.However,no significant difference in fettitin was found between the two pulmonary infection group(P〈 all0.01).The serum levels of CA125 and CA15-3 in patients with pleural fluid were significantly higher than that in patients with only pulmonary infection and controls(P〈0.05,P〈0.01).In patients with pleural fluid,the levels of ferritin and CA125 in pleural fluid were significantly higher than in serum(P all〈0.01).Moreover,the level of ferritin in pleural fluid was significantly correlated with that in serum(r=0.537,P〈0.05).Conclusion: Serum levels of several tumor markers of patients with pulmonary infection are abnormal.The higher serum level of tumor markers is associated with production of pleural fluid.
出处 《中国卫生检验杂志》 CAS 2010年第8期1966-1967,共2页 Chinese Journal of Health Laboratory Technology
关键词 肿瘤标志物 蛋白芯片 肺感染 胸水 Tumor markers Protein biochip Pulmonary infection Pleural fluid
  • 相关文献

参考文献6

二级参考文献38

  • 1潘秀军,王连升,沈霞.多肿瘤标志物蛋白芯片技术在肺癌诊断中的应用[J].上海第二医科大学学报,2005,25(8):839-841. 被引量:6
  • 2赵继宗,吴博恒.消化道肿瘤相关抗原CA_(19-9)的临床应用研究[J].癌症,1996,15(2):141-142. 被引量:10
  • 3董淑文,丁彦,邱小建,高菲,韦秀萍,党斌温,张杰.多肿瘤标志物蛋白芯片检测方法对肺癌的诊断研究[J].中国医师进修杂志(内科版),2006,29(2):20-22. 被引量:6
  • 4Schneider J,Peltri G,Bitterlich N,et al.Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.Anticancer Res,2003,23 (2A):899-906.
  • 5Paweletz CP,Gillespie JW,Omstein DK,et al.Rapid protein display profiling of cancer progession directly from human tissue using a protein biochip.Deve Res,2000,49(1):34.
  • 6Eggeling F,Davies H,Lomas L,et al.Tissue-specific microdissecrion coupled with proteinchip array technologies:applications in cancer ressarch.Biotechniques,2000,29 (1):1066.
  • 7Sun Z,Fu X,Zhang L,et al.A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection.Anticancer Res,2004,24(2C):1159-1165.
  • 8Eggeling F,Davies H,Lomas L,et al.Tissue-specific microdissection coupled with protein chip array technologies:applications in cancer research[J].Biotechniques,2000;29:1066-70.
  • 9Foa P,Fornier M,Miceli R,et al.Tumour markers CEA,NSE,SCC,TPA and CYFRA 21.1 in resectable non-small cell lung cancer[J].Anticancer Res,1999;19:3613-8.
  • 10Body JJ,Sculier JP,Raymakers N,et al.Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer[J].Cancer,1990;65:1552-6.

共引文献448

同被引文献13

  • 1俞小芳,林静,徐夏莲,叶志斌.蛋白尿和血清白蛋白水平对血清肿瘤标志物水平的影响[J].复旦学报(医学版),2006,33(3):305-308. 被引量:5
  • 2俞小芳,徐夏莲,叶志斌,林静.慢性肾脏病患者血清肿瘤标志物的表达及其相关因素分析[J].中国实用内科杂志:临床前沿版,2006,26(10):1617-1620. 被引量:4
  • 3付煜,沈华,公益明,邱宁岩,张静馨,李惠萍.南京市1928例单位体检人群AFP、CEA、PSA检测分析[J].南京医科大学学报(自然科学版),2007,27(2):202-203. 被引量:6
  • 4Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition andclassification of chronic kidney disease ; a position statementfrom Kidney Disease: Improving Global Outcomes (KDIGO)[J]. Kidney Int,2005, 67(6): 2089-2100.
  • 5Meyskens FL Jr, Curt GA, Brenner DE, et al. Regulatoryapproval of cancer risk-reducing (chemopreventive) drugs:moving what we have learned into the clinic [J]. Cancer PrevRes (Phila), 2011,4 (3): 311-323.
  • 6Shimojo N, Naka K, Nakajima C,et al. The effect of non-insulin-dependent diabetes on serum concentrations of tumor-as-sociated carbohydrate antigens of CA19-9, CA-50, and SSEA-1in association with the Lewis blood phenotype [J]. Clin ChimActa, 1990, 190 (3) : 283-289.
  • 7Arik N, Adam B, Akpolat T, et al. Serum tumour markersin renal failure [J]. Int Urol Nephrol, 1996,28 (4):601-604.
  • 8Loeb S, Gonzalez CM, Roehl KA, et al. Pathologicalcharacteristis of prostate cancer detected through prostate speci-fic antigen based screening [J]. J Urol, 2006, 175 (3 Pt 1):902-906.
  • 9Pansadoro V, Emiliozzi P, Defidio L, etal. Prostate-specificantigen and prostatitis in men under fifty [J]. Eur Urol, 1996,30(1): 24-27.
  • 10Sevinc A, Buyukberber S, Sari R, et al. Elevated serumCA-125 levels in patients with nephritic syndrome-induced as-cites [J]. Anticancer Res, 2000, 20 ( 2B) : 1201-1203.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部